Alma Technologies Launches Scalable Encoder and Decoder Semiconductor IP for VESA DSC 1.2b Visually Lossless Compression
30.3.2022 15:01:00 EEST | Business Wire | Press release
IP Highlights:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220330005026/en/
Extending Alma Technologies UHT™ Image & Video Compression product line, the new UHT-DSC-E and UHT-DSC-D IP cores provide ultra-low latency visually lossless compression across display interfaces and devices. (Graphic: Business Wire)
- Fully compliant with VESA DSC 1.2b and backwards compatible with DSC 1.1
- Ultra-low latency visually lossless image compression for all types of content
- Scalable architecture supporting up to 10K @120Hz with native pixel coding and up to 16 bits per color for high color depth and HDR content
- Compatible with major transport standards including MIPI DSI, VESA DisplayPort 1.4 and HDMI 2.1
Alma Technologies S.A. today announced its new UHT-DSC-E and UHT-DSC-D DSC 1.2b encoder and decoder IP cores that enable the transport of high-definition content with up to 10K resolution, 120Hz refresh rate, high dynamic range and high color depth through existing interfaces, such as VESA DisplayPort, MIPI DSI and HDMI 2.1.
Extending Alma Technologies UHTTM Image and Video Compression family of JPEG, JPEG 2000 and H.264 IP, these ultra-high throughput and scalable performance semiconductor IP implementations of the DSC 1.2b standard provide a fully accelerated, standalone and robust compression solution in a single IP instance, saving on ASIC or FPGA silicon area and power. The cores do not need an external memory device for their implementation and lower power consumption for longer battery life is further enabled by the reduced video interface data rates and video buffer sizes.
The new Alma Technologies encoder and decoder IP cores for DSC 1.2b are very easy-to-use and integrate in a system. They are self-contained, CPU-less, complete H/W implementations and are available either in RTL source code, or as pre-synthesized Netlists for all major FPGA vendor devices.
Contact us online at www.alma-technologies.com/contact, or call us at +30-210-603-9850 to learn more.
About Alma Technologies
Alma Technologies is a semiconductor IP provider, designing high-quality FPGA and ASIC IP cores since 2001. Its products stand out for their engineering, being complete, easy-to-use and reliable IP solutions. World-class technical support and a long track record of proven designs by more than 250 licensees in over 20 countries provide Alma Technologies customers with excellent service and great value.
UHT is a trademark of Alma Technologies.
All other trademarks and trade names are the property of their respective owners.
###
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005026/en/
Contact information
Vassilis Spiliotopoulos
media@alma-technologies.com
+30-210-603-9850 ext.107
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
